Site-specific PEGylation of HR2 peptides: Effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation

Bioconjugate Chemistry

Volumn 23, Issue 8, 2012, Pages 1648-1660

  Danial, Maarten ^a   Van Dulmen, Tim H H ^a   Aleksandrowicz, Joanna ^b   Pötgens, Andy J G ^b   Klok, Harm Anton ^a  

^a EPFL   (Switzerland)

^b AplaGen GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; CELL MEMBRANES; CHAINS; CYTOLOGY; DISEASES; PEPTIDES; STABILITY; VIRUSES;

CHAINS LENGTH; ENVELOPE GLYCOPROTEINS; HALF LIVES; MEMBRANE FUSION; PEGYLATION; PEPTIDE PROTEINS; PROTEOLYTIC DEGRADATION; PROTEOLYTIC STABILITY; SITE-SPECIFIC; WILD TYPES;

POLYETHYLENE GLYCOLS;

ETHYLENE GLYCOL; TRYPSIN;

ALPHA HELIX; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CELL ASSAY; CONJUGATE; CONJUGATION; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; MEMBRANE FUSION; MOLECULAR WEIGHT; NONHUMAN; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN STABILITY;

EID: 84865113199     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc3002248     Document Type: Article

References (44)

1. Cohen, J. (2007) New estimates scale back scope of HIV/AIDS epidemic Science 318, 1360-1361 (Pubitemid 350208923)
2. Mehellou, Y. and De Clercq, E. (2010) Twenty-six years of anti-HIV drug discovery: Where do we stand and where do we go? J. Med. Chem. 53, 521-538
3. Wild, C., Greenwell, T., and Matthews, T. (1993) A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion AIDS Res. Hum. Retroviruses 9, 1051-1053
4. De Clercq, E. (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV Int. J. Antimicrob. Agents 33, 307-320
5. Eggink, D., Berkhout, B., and Sanders, R. W. (2010) Inhibition of HIV-1 by fusion inhibitors Curr. Pharm. Des. 16, 3716-3728
6. Fuzeon Product Information, http://www.fuzeon.com.
7. Veronese, F. M. (2001) Peptide and protein PEGylation: A review of problems and solutions Biomaterials 22, 405-417 (Pubitemid 32007845)
8. Caliceti, P. and Veronese, F. M. (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv. Drug Delivery Rev. 55, 1261-1277 (Pubitemid 37464561)
9. Pasut, G. and Veronese, F. M. (2007) Polymer-drug conjugation, recent achievements and general strategies Prog. Polym. Sci. (Oxford, U.K.) 32, 933-961 (Pubitemid 47198290)
10. Klok, H.-A. (2009) Peptide/protein-synthetic polymer conjugates-Quo vadis Macromolecules 42, 7990-8000
11. Caliceti, P., Salmaso, S., Walker, G., and Bernkop-Schnurch, A. (2004) Development and in vivo evaluation of an oral insulin-PEG delivery system Eur. J. Pharm. Sci. 22, 315-323 (Pubitemid 38758019)
12. Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W. J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z. X., Modi, M. W., Farid, A., and Berthold, W. (2001) Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C Bioconjugate Chem. 12, 195-202 (Pubitemid 32235471)
13. Kochendoerfer, G. G., Chen, S. Y., Mao, F., Cressman, S., Traviglia, S., Shao, H., Hunter, C. L., Low, D. W., Cagle, E. N., Carnevali, M., Gueriguian, V., Keogh, P. J., Porter, H., Stratton, S. M., Con Wiedeke, M., Wilken, J., Tang, J., Levy, J. J., Miranda, L. P., Crnogorac, M. M., Kalbag, S., Botti, P., Schindler-Horvat, J., Savatski, L., Adamson, J. W., Kung, A., Kent, S. B. H., and Bradburne, J. A. (2003) Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein Science 299, 884-887 (Pubitemid 36182445)
14. Roberts, M. J., Bentley, M. D., and Harris, J. M. (2002) Chemistry for peptide and protein PEGylation Adv. Drug Delivery Rev. 54, 459-476 (Pubitemid 34615543)
15. Gauthier, M. A. and Klok, H.-A. (2008) Peptide/protein-polymer conjugates: Synthetic strategies and design concepts Chem. Commun. 2591-2611 (Pubitemid 351793824)
16. Bailon, P. and Won, C. Y. (2009) PEG-modified biopharmaceuticals Expert Opin. Drug Delivery 6, 1-16
17. Doherty, D. H., Rosendahl, M. S., Smith, D. J., Hughes, J. M., Chlipala, E. A., and Cox, G. N. (2005) Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor Bioconjugate Chem. 16, 1291-1298 (Pubitemid 41368133)
18. Salhanick, A. I., Clairmont, K. B., Buckholz, T. M., Pellegrino, C. M., Ha, S., and Lumb, K. J. (2005) Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide Bioorg. Med. Chem. Lett. 15, 4114-4117 (Pubitemid 41132672)
19. Yamamoto, Y., Tsutsumi, Y., Yoshioka, Y., Nishibata, T., Kobayashi, K., Okamoto, T., Mukai, Y., Shimizu, T., Nakagawa, S., Nagata, S., and Mayumi, T. (2003) Site-specific pegylation of a lysine-deficient TNF-α with full bioactivity Nat. Biotechnol. 21, 546-552 (Pubitemid 36532020)
20. Welch, B. D., VanDemark, A. P., Heroux, A., Hill, C. P., and Kay, M. S. (2007) Potent D-peptide inhibitors of HIV-1 entry Proc. Natl. Acad. Sci. U.S.A. 104, 16828-16833 (Pubitemid 350210950)
21. Bailon, P. S. and Won, C.-Y. (2004) PEGylated T20 Polypeptide. WO/2004/013164.
22. Bailon, P. S. and Won, C.-Y. (2004) PEGylated T1249 Polypeptide. WO/2004/013165.
23. Stoddart, C. A., Nault, G., Galkina, S. A., Thibaudeau, K., Bakis, P., Bousquet-Gagnon, N., Robitaille, M., Bellomo, M., Paradis, V., Liscourt, P., Lobach, A., Rivard, M. È., Ptak, R. G., Mankowski, M. K., Bridon, D., and Quraishi, O. (2008) Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: Equipotent to C34 and T-20 in vitro with sustained activity in SCID-HU THY/LIV mice J. Biol. Chem. 283, 34045-34052
24. Huet, T., Kerbarh, O., Schols, D., Clayette, P., Gauchet, C., Dubreucq, G., Vincent, L., Bompais, H., Mazinghien, R., Querolle, O., Salvador, A., Lemoine, J., Lucidi, B., Balzarini, J., and Petitou, M. (2010) Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity Antimicrob. Agents Chemother. 54, 134-142
25. Weiss, C. D. and White, J. M. (1993) Characterization of stable Chinese hamster ovary cells expressing wild- type, secreted, and glycosylphosphatidylinositol-anchored human immunodeficiency virus type 1 envelope glycoprotein J. Virol. 67, 7060-7066 (Pubitemid 23343831)
26. Palasek, S. A., Cox, Z. J., and Collins, J. M. (2007) Limiting racemization and aspartimide formation in microwave-enhanced Fmoc solid phase peptide synthesis J. Pept. Sci. 13, 143-148 (Pubitemid 46421009)
27. Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., and Gray, T. (1995) How to measure and predict the molar absorption coefficient of a protein Protein Sci. 4, 2411-2423
28. Chen, Y. H., Yang, J. T., and Chau, K. H. (1974) Determination of the helix and β form of proteins in aqueous solution by circular dichroism Biochemistry 13, 3350-3359
29. http://www.jphilo.mailway.com/download.htm.
30. http://www.analyticalultracentrifugation.com/sedphat/sedphat.htm.
31. Dwyer, J. J., Hasan, A., Wilson, K. L., White, J. M., Matthews, T. J., and Delmedico, M. K. (2003) The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation Biochemistry 42, 4945-4953 (Pubitemid 36532047)
32. Muñoz-Barroso, I., Durell, S., Sakaguchi, K., Appella, E., and Blumenthal, R. (1998) Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41 J. Cell Biol. 140, 315-323 (Pubitemid 28078395)
33. http://rsbweb.nih.gov/ij/.
34. Gallo, S. A., Finnegan, C. M., Viard, M., Raviv, Y., Dimitrov, A., Rawat, S. S., Puri, A., Durell, S., and Blumenthal, R. (2003) The HIV Env-mediated fusion reaction Biochim. Biophys. Acta 1614, 36-50 (Pubitemid 36857094)
35. Chan, D. C. and Kim, P. S. (1998) HIV entry and its inhibition Cell 93, 681-684 (Pubitemid 28257575)
36. Lu, M., Blacklow, S. C., and Kim, P. S. (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein Nat. Struct. Biol. 2, 1075-1082
37. Bianchi, E., Finotto, M., Ingallinella, P., Hrin, R., Carella, A. V., Hou, X. S., Schleif, W. A., Miller, M. D., Geleziunas, R., and Pessi, A. (2005) Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection Proc. Natl. Acad. Sci. U.S.A. 102, 12903-12908 (Pubitemid 41279462)
38. Eggink, D., Langedijk, J. P. M., Bonvin, A. M. J. J., Deng, Y., Lu, M., Berkhout, B., and Sanders, R. W. (2009) Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors J. Biol. Chem. 284, 26941-26950
39. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. C. (1997) Atomic structure of the ectodomain from HIV-1 gp41 Nature 387, 426-430 (Pubitemid 27227210)
40. Chan, D. C., Chutkowski, C. T., and Kim, P. S. (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target Proc. Natl. Acad. Sci. U.S.A. 95, 15613-15617 (Pubitemid 29018748)
41. Smith, S. D., Morgan, R., and Link, M. P. (1986) Cytogenetic and immunophenotypic analysis of cell lines established from patients with T cell leukemia/lymphoma Blood 67, 650-656 (Pubitemid 16130252)
42. Buzon, V., Natrajan, G., Schibli, D., Campelo, F., Kozlov, M. M., and Weissenhorn, W. (2010) Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions PLoS Pathog. 6, e1000880
43. Rosendahl, M. S., Doherty, D. H., Smith, D. J., Carlson, S. J., Chlipala, E. A., and Cox, G. N. (2005) A long-acting, highly potent interferon α-2 conjugate created using site-specific PEGylation Bioconjugate Chem. 16, 200-207 (Pubitemid 40129694)
44. http://www.sigmaaldrich.com/life-science/metabolomics/enzyme-explorer/ analytical-enzymes/trypsin.html.